Entera Bio Ltd (ENTX)

Currency in USD
1.981
+0.031(+1.57%)
Real-time Data·
ENTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ENTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.9602.036
52 wk Range
1.4102.790
Key Statistics
Prev. Close
1.95
Open
1.96
Day's Range
1.96-2.036
52 wk Range
1.41-2.79
Volume
1.23K
Average Volume (3m)
43.48K
1-Year Change
11.43%
Book Value / Share
0.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ENTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.000
Upside
+404.80%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Entera Bio Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Strong Buy

Entera Bio Ltd Company Profile

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.

Compare ENTX to Peers and Sector

Metrics to compare
ENTX
Peers
Sector
Relationship
P/E Ratio
−8.8x−2.1x−0.5x
PEG Ratio
−1.010.000.00
Price/Book
4.6x3.5x2.6x
Price / LTM Sales
397.5x8.9x3.2x
Upside (Analyst Target)
-428.6%42.7%
Fair Value Upside
Unlock7.3%5.8%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 10.000
(+404.80% Upside)

Earnings

Latest Release
May 09, 2025
EPS / Forecast
-0.06 / -0.07
Revenue / Forecast
42.00K / --
EPS Revisions
Last 90 days

ENTX Income Statement

People Also Watch

2.735
ACHV
+3.21%
13.240
CBIO
+1.53%
10.900
HYPD
-5.38%
58.620
ASTS
+2.68%

FAQ

What Stock Exchange Does Entera Bio Trade On?

Entera Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Entera Bio?

The stock symbol for Entera Bio is "ENTX."

What Is the Entera Bio Market Cap?

As of today, Entera Bio market cap is 90.04M.

What Is Entera Bio's Earnings Per Share (TTM)?

The Entera Bio EPS (TTM) is -0.26.

When Is the Next Entera Bio Earnings Date?

Entera Bio will release its next earnings report on 07 Aug 2025.

From a Technical Analysis Perspective, Is ENTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Entera Bio Stock Split?

Entera Bio has split 0 times.

How Many Employees Does Entera Bio Have?

Entera Bio has 19 employees.

What is the current trading status of Entera Bio (ENTX)?

As of 23 Jul 2025, Entera Bio (ENTX) is trading at a price of 1.98, with a previous close of 1.95. The stock has fluctuated within a day range of 1.96 to 2.04, while its 52-week range spans from 1.41 to 2.79.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.